CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Mepyramine

美吡拉敏 杂质对照品Mepyramine Impurities

EP31 个杂质条目31 impurity entries

本页汇总 美吡拉敏 的 31 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 31 impurity reference standards of Mepyramine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 美吡拉敏(Mepyramine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSimultaneous Determination of Dexpanthenol, Lidocaine Hydrochloride, Mepyramine Maleate and their Related Substances by a RP-HPLC Method in Topical Dosage Forms
    Journal of chromatographic science · 2018 · Doganay A et al.  ·  PMID 30085004  ·  DOI
  2. 分析方法Analytical MethodsHigh-performance liquid chromatographic determination of mepyramine maleate, pheniramine maleate and phenylpropanolamine hydrochloride in tablets and drops
    The Analyst · 1987 · el-Gizawy SM, Ahmed Ael H  ·  PMID 3619056  ·  DOI
  3. 分析方法Analytical MethodsDetermination of age-related changes of cytochrome P-450 sensitive to mepyramine in rat hepatic microsomes
    Yao xue xue bao = Acta pharmaceutica Sinica · 1995 · Wang NP et al.  ·  PMID 8701726
  4. 分析方法Analytical MethodsDetermination of mepyramine, aminophenazone, nialamide and chloroquine using the deltapj method
    Die Pharmazie · 1978 · Wahbi AM et al.  ·  PMID 27823

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisA convenient synthesis of [3H]mepyramine and certain related [3H]antihistamines
    The Journal of pharmacy and pharmacology · 1978 · Marrian DH et al.  ·  PMID 30827  ·  DOI

美吡拉敏 —— 原料药与杂质对照品Mepyramine — drug substance & impurities

共 32 个条目(含原料药本体)32 items incl. the drug substance
Mepyramine structure
EP原料药 APIAPI
美吡拉敏Mepyramine
Mepyramine
CAS No.91-84-9
Chemical FormulaC17H23N3O
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 1 (Mepyramine Maleate EP Impurity A) structure
EPA
美吡拉敏杂质1 (马来酸美吡拉敏EP杂质A)Mepyramine Impurity 1 (Mepyramine Maleate EP Impurity A)
Mepyramine Impurity 1 (Mepyramine Maleate EP Impurity A)
CAS No.52818-63-0
Chemical FormulaC13H14N2O
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 4 (N-Desmethyl Mepyramine) structure
4
美吡拉敏杂质4 (N-去甲基 美吡拉敏)Mepyramine Impurity 4 (N-Desmethyl Mepyramine)
Mepyramine Impurity 4 (N-Desmethyl Mepyramine)
CAS No.104499-47-0
Chemical FormulaC16H21N3O
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 4 Maleate (N-Desmethyl Mepyramine Maleate) structure
4
美吡拉敏杂质4 马来酸盐 (N-去甲基 美吡拉敏 马来酸盐)Mepyramine Impurity 4 Maleate (N-Desmethyl Mepyramine Maleate)
Mepyramine Impurity 4 Maleate (N-Desmethyl Mepyramine Maleate)
CAS No.1350043-42-3
Chemical FormulaC16H21N3O·C4H4O4
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 5 Dihydrochloride (Mepyramine N-Oxide Dihydrochloride) structure
5
美吡拉敏杂质5 双盐酸盐 (美吡拉敏氮氧化物双盐酸盐)Mepyramine Impurity 5 Dihydrochloride (Mepyramine N-Oxide Dihydrochloride)
Mepyramine Impurity 5 Dihydrochloride (Mepyramine N-Oxide Dihydrochloride)
CAS No.2724726-88-7
Chemical FormulaC17H23N3O2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 5 (Mepyramine N-Oxide) structure
5
美吡拉敏杂质5 (美吡拉敏 氮氧化物)Mepyramine Impurity 5 (Mepyramine N-Oxide)
Mepyramine Impurity 5 (Mepyramine N-Oxide)
CAS No.98982-99-1
Chemical FormulaC17H23N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 6 structure
6
美吡拉敏杂质6Mepyramine Impurity 6
Mepyramine Impurity 6
CAS No.3815-30-3
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 7 structure
7
美吡拉敏杂质7Mepyramine Impurity 7
Mepyramine Impurity 7
CAS No.104-27-8
Chemical FormulaC12H14O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 8 structure
8
美吡拉敏杂质8Mepyramine Impurity 8
Mepyramine Impurity 8
CAS No.943-88-4
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 9 structure
9
美吡拉敏杂质9Mepyramine Impurity 9
Mepyramine Impurity 9
CAS No.103-13-9
Chemical FormulaC13H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 10 structure
10
美吡拉敏杂质10Mepyramine Impurity 10
Mepyramine Impurity 10
CAS No.20766-31-8
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 11 structure
11
美吡拉敏杂质11Mepyramine Impurity 11
Mepyramine Impurity 11
CAS No.2419-67-2
Chemical FormulaC14H18O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 12 structure
12
美吡拉敏杂质12Mepyramine Impurity 12
Mepyramine Impurity 12
CAS No.30625-53-7
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 13 structure
13
美吡拉敏杂质13Mepyramine Impurity 13
Mepyramine Impurity 13
CAS No.943-87-3
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 14 structure
14
美吡拉敏杂质14Mepyramine Impurity 14
Mepyramine Impurity 14
CAS No.74975-53-4
Chemical FormulaC16H22O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 15 structure
15
美吡拉敏杂质15Mepyramine Impurity 15
Mepyramine Impurity 15
CAS No.114591-18-3
Chemical FormulaC13H14O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 16 structure
16
美吡拉敏杂质16Mepyramine Impurity 16
Mepyramine Impurity 16
CAS No.62378-72-7
Chemical FormulaC13H14O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 17 structure
17
美吡拉敏杂质17Mepyramine Impurity 17
Mepyramine Impurity 17
CAS No.4842-69-7
Chemical FormulaC18H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 18 structure
18
美吡拉敏杂质18Mepyramine Impurity 18
Mepyramine Impurity 18
CAS No.97432-38-7
Chemical FormulaC21H20O4
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 19 structure
19
美吡拉敏杂质19Mepyramine Impurity 19
Mepyramine Impurity 19
CAS No.114591-25-2
Chemical FormulaC20H18O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 20 structure
20
美吡拉敏杂质20Mepyramine Impurity 20
Mepyramine Impurity 20
CAS No.1698017-22-9
Chemical FormulaC13H14O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 21 structure
21
美吡拉敏杂质21Mepyramine Impurity 21
Mepyramine Impurity 21
CAS No.458533-66-9
Chemical FormulaC19H18O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 22 structure
22
美吡拉敏杂质22Mepyramine Impurity 22
Mepyramine Impurity 22
CAS No.94638-92-3
Chemical FormulaC13H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 23 structure
23
美吡拉敏杂质23Mepyramine Impurity 23
Mepyramine Impurity 23
CAS No.67962-14-5
Chemical FormulaC13H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 24 structure
24
美吡拉敏杂质24Mepyramine Impurity 24
Mepyramine Impurity 24
CAS No.30669-46-6
Chemical FormulaC13H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 25 structure
25
美吡拉敏杂质25Mepyramine Impurity 25
Mepyramine Impurity 25
CAS No.39728-67-1
Chemical FormulaC13H16O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 26 structure
26
美吡拉敏杂质26Mepyramine Impurity 26
Mepyramine Impurity 26
CAS No.371246-71-8
Chemical FormulaC18H16O3
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 27 structure
27
美吡拉敏杂质27Mepyramine Impurity 27
Mepyramine Impurity 27
CAS No.173933-40-9
Chemical FormulaC12H12O4
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 30 structure
30
美吡拉敏杂质30Mepyramine Impurity 30
Mepyramine Impurity 30
CAS No.109912-36-9
Chemical FormulaC18H26N4O
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 31 structure
31
美吡拉敏杂质31Mepyramine Impurity 31
Mepyramine Impurity 31
CAS No.591-31-1
Chemical FormulaC8H8O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 32 structure
32
美吡拉敏杂质32Mepyramine Impurity 32
Mepyramine Impurity 32
CAS No.612-16-8
Chemical FormulaC8H10O2
Purity>95%询价On request
10mg25mg50mg100mg
Mepyramine Impurity 33 structure
33
美吡拉敏杂质33Mepyramine Impurity 33
Mepyramine Impurity 33
CAS No.2120-70-9
Chemical FormulaC8H8O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

美吡拉敏 —— 研究文献与合成路线Mepyramine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 美吡拉敏 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Mepyramine. Titles link to the original records; copyright remains with the authors and publishers.

合成路线文献Synthetic-route papers

  1. Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine
    Li L, Kracht J, Peng S, et al. · Bioorganic & medicinal chemistry letters · 2003
  2. A convenient synthesis of [3H]mepyramine and certain related [3H]antihistamines
    Marrian DH, Hill SJ, Sanders JK, et al. · The Journal of pharmacy and pharmacology · 1978
  3. Letter: The redirection of glyceride and phospholipid synthesis by drugs including chlorpromazine, fenfluramine, imipramine, mepyramine and local anaesthetics
    Brindley DN, Allan D, Michell RH · The Journal of pharmacy and pharmacology · 1975

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

美吡拉敏 杂质谱研究要点Mepyramine — impurity profiling notes

下面这些是拿到 美吡拉敏 的 32 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 32 impurity entries for Mepyramine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances